Oxurion Announces Second Amendment to Negma Funding Program
OxurionAnnouncesSecond AmendmenttoNegma FundingProgram
Leuven, BELGIUM, Boston, MA, US – January 25, 20238:30 am – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has further amended its mandatory convertible bonds issuance and subscription agreement with the Negma Group (“funding program”).
Since the start of the funding program in September 2021, Negma has subscribed to EUR 11 million in convertible bonds. Pursuant to the amendment, Negma agrees to subscribe to up to EUR 4 million (1,600 bonds) in three tranches to be called at Oxurion’s discretion. The initial funding program totaled EUR 30 million in two parts, and pursuant to the amendment, Oxurion and Negma have mutually agreed to wind-down the funding program after the completion of the first part, which reduces the total funding under the funding program to EUR 15 million. Negma has waived the liquidity requirement and agreed to a reduced cool down period of 15 trading days, allowing Oxurion to access the full EUR 4 million over less than two months starting in February 2023 (provided the other terms and conditions of the agreement and the bonds are met).
While Oxurion continues to carefully manage its cash requirements, the Negma funding alone is not sufficient to finish Oxurion’s ongoing KALAHARI Phase 2, Part B clinical trial. Oxurion therefore continues to seek additional funding through debt, equity, or non-dilutive funding to support the KALAHARI trial. The KALAHARI trial is evaluating THR-149, Oxurion’s novel therapeutic for second line therapy, against market leader aflibercept, for the treatment of diabetic macular edema (DME) for the 40-50% of DME patients that respond suboptimally to standard of care anti-VEGF therapy. The KALAHARI trial has recruited more than 50% of the patients and topline data is currently expected before the end of 2023.
“The urgency for novel therapeutics like THR-149 that could treat DME, the leading cause of blindness in working age adults, remains critical,” said Tom Graney, CEO of Oxurion. “Recent interim analysis of Part B of our two-part Phase 2 clinical trial of THR-149 indicated that our study should continue. We are on track to have topline results later this year as we advance our approach to developing the next generation standard of care for retinal disorders.”
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
|Oxurion NV Tom Graney|
Chief Executive Officer Tel: +32 16 75 13 10
Mary T. Conway
Chief Business Officer Tel: +32 479 783583
|ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304|
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Freshworks and Meta Partner to Help Businesses Elevate Conversational Customer Experience Through the World’s Most Popular Messaging Apps6.2.2023 13:00:00 CET | Press release
Powered by the Freshworks Neo platform, the Freshworks CX and CRM integrations with WhatsApp, Instagram Messaging, and Facebook Messenger, enable teams to deliver intelligent and personalized messages at scale SAN MATEO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Freshworks Inc. (NASDAQ: FRSH) today announced that companies around the world have increased customer retention by using Freshworks’ conversational AI bots to automate communication with buyers through WhatsApp, Instagram Messaging, and Facebook Messenger. International companies like MTN Cameroon in Africa, Body & Fit in Europe and The Giving Movement in Dubai have elevated their customer support efficiency on Meta’s messaging platforms using Freshworks’ Freshchat™, Freshdesk™ and Freshsales™ products. With over two billion daily active WhatsApp users, nearly two billion daily active Facebook users, and more than two billion monthly active Instagram users, Meta provides the world’s most popular messaging platforms. The Meta B
Online Retailer Das Kostümland Deploys Descartes’ Ecommerce Warehouse Management Solution to Strengthen Peak Season Fulfillment6.2.2023 12:45:00 CET | Press release
MUNICH, Germany and ATLANTA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Das Kostümland, a leading German vendor of costumes and disguises, has deployed Descartes’ ecommerce warehouse management system (WMS) to keep pace with dramatic order volume seasonal spikes. The Descartes solution streamlines and accelerates the retailer’s fulfillment processes, increasing operational efficiency, reducing costs, and enhancing the customer experience. “We have more than 10,000 SKUs and, during seasonal peaks such as Halloween, we process upwards of 2,000 orders per day,” said Daria May, founder and CEO of Das Kostümland. “With Descartes’ barcode-based pick and pack processes, we’ve increased our warehouse productivity to handle even extreme seasonal order fluctuations without hiring additional labor. By optimizing our fulfillment processes, we’ve reduced picking errors,
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression6.2.2023 12:30:00 CET | Press release
Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority review and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. “We see potential for zuranolone, if approved, to be a meaningful new option that can help address the serious unmet need faced by the diverse pop
Maha Energy enters into a definitive agreement regarding the business combination with DBO 2.0 S.A.6.2.2023 12:05:00 CET | Press release
Maha Energy AB (publ) (“Maha” or the ”Company”) is pleased to announce that it has signed the definitive agreement with the shareholders of DBO 2.0 S.A. (“DBO”), with respect to the previously announced (on December 5, 2022) business combination, which involves (i) a maximum issuance of 36,775,410 new shares in Maha, to be subscribed by DBO’s shareholders as a consideration; and (ii) the transfer of DBO’s existing shares to Maha by DBO’s shareholders (“Transaction”). The Transaction is subject to customary conditions precedent, including an Extraordinary General Meeting in Maha approving the necessary resolutions. The Transaction is expected to close in the 1st half of 2023. Founded in 2017, DBO is a private upstream oil and gas company that focus on mature offshore fields in Brazil. It has attracted North Sea investors to invest in Brazilian assets, working with Brazilian partners, and applying the most advanced Northern Sea techniques in order to: (1) identify additional reserves, (2
Maha Energy sluter slutgiltigt avtal avseende sammanslagning av verksamheterna med DBO 2.0 S.A.6.2.2023 12:05:00 CET | Pressemelding
Maha Energy AB (publ) (“Maha” eller ”Bolaget”) meddelar härmed att Bolaget har slutit ett slutgiltigt avtal med aktieägarna till DBO 2.0 S.A. (”DBO”) avseende den tidigare överenskomna och den 5 december 2022 offentliggjorda sammanslagning av verksamheterna, vilken inkluderar (i) en köpeskilling om maximalt 36 775 410 nyemitterade aktier i Maha som tecknas av DBOs aktieägare,: och (ii) att aktieägarna i DBO överför aktierna i DBO till Maha (”Transaktionen”). Transaktionen är villkorad sedvanliga förbehåll, inklusive en extra bolagsstämma i Maha för att fatta de nödvändiga besluten. Transaktionen beräknas kunna slutföras under första halvåret 2023. DBO är ett privat upstream olje- och gasbolag med fokus på mogna offshorefält i Brasilien. DBO grundades 2017 och har attraherat Nordsjöinvesterare att investera i brasilianska tillgångar, arbeta med brasilianska partners och tillämpa de mest avancerade teknikerna från Nordsjön för att (1) identifiera ytterligare reserver, (2) utveckla mogna